Brief: Genor Biopharma Says NMPA Granted New Drug Application Approval For Lerociclib (Gb491)
29/05/2025 11:35
May 29 (Reuters) - Genor Biopharma Holdings Ltd 6998.HK: NMPA GRANTED NEW DRUG APPLICATION APPROVAL FOR LEROCICLIB (GB491) Further company coverage: 6998.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edding Genor group
See all newsBrief: Edding Genor Says CEO Initiates Plan To Purchase Additional Shares In Open Market
Brief: Edding Genor Posts Net Profit Increased To Rmb399.3 Million In 2025
Brief: Genor Biopharma Says NMPA Granted New Drug Application Approval For Lerociclib (Gb491)
Brief: Genor Biopharma, Its Unit & Edding Group Entered Into Merger Agreement
Brief: Genor Biopharma Says Guo Feng Tendered His Resignation As Chairman